Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Market OverviewThe Global RNA Therapeutics Market is valued at USD 13.3 Billion in 2023 and is projected to reach a value ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently ...

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) had its target price raised by analysts at HC Wainwright from $35.00 to $47.00 in a research note issued on Tuesday,Benzinga reports. The firm ...

Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...